U.S. Industrial REITs Stock News

NYSE:HL
NYSE:HLMetals and Mining

Hecla Mining (HL) Is Up 5.9% After Going Debt Free With Record Free Cash Flow – Has The Bull Case Changed?

In the first quarter of 2026, Hecla Mining Company reported sales of US$411.43 million but booked a net loss of US$19.03 million, declared common and preferred dividends, and increased silver production to 3.9 million ounces, about 3% above the prior quarter. The combination of a debt-free balance sheet, record free cash flow from continuing operations, and a renewed focus on silver growth projects marks a significant shift in how Hecla funds expansion and rewards shareholders. With Hecla...
NYSE:CSR
NYSE:CSRResidential REITs

A Look At Centerspace (CSR) Valuation After Q1 2026 Results And Reaffirmed 2026 Outlook

Centerspace (CSR) drew fresh attention after reporting Q1 2026 results that included lower sales, a wider net loss, and a reaffirmed outlook calling for flat to modest same-store revenue growth this year. See our latest analysis for Centerspace. The stock has had a mixed year, with a 30 day share price return of 5.84% and a 1 year total shareholder return of 16%. This suggests momentum has been building even as Q1 results and the ongoing review keep risks front of mind. If this kind of...
NYSEAM:IE
NYSEAM:IEMetals and Mining

Why Ivanhoe Electric (IE) Is Up 12.2% After Alacrán Sale Boosts Profit And Funds Exploration

Ivanhoe Electric’s first-quarter 2026 results showed sales of US$858,000 and net income of US$41.74 million, a sharp turnaround from a net loss a year earlier, largely reflecting a very large gain from subsidiary Cordoba’s sale of the Alacrán copper-gold project. Alongside this profit swing, Ivanhoe Electric increased exploration spending at assets such as the Santa Cruz Copper Project and entered new copper-focused collaborations, including a partnership with SQM Chile, reshaping how...
NYSE:SON
NYSE:SONPackaging

Will Sonoco’s (SON) ESOP Share Issuance and Earnings Quality Scrutiny Recast Its Profit Narrative?

In late April 2026, Sonoco Products Company filed a US$71.37 million shelf registration for 1,430,000 common shares tied to an ESOP-related offering. While the company recently reported strong earnings, the reliance on unusual items and flagged warning signs has raised questions about the quality and durability of its profit profile. We’ll now explore how the ESOP-related share issuance and questions over earnings quality intersect with Sonoco’s existing investment narrative. Uncover the...
NYSE:BIP
NYSE:BIPIntegrated Utilities

Does Brookfield Infrastructure Partners’ Rising FFO Amid Net Loss Reframe Its Cash-Flow Story for BIP Investors?

Brookfield Infrastructure Partners L.P. reported past first-quarter 2026 results with revenue rising to US$6,301 million from US$5,392 million, while limited partners recorded a net loss of US$86 million versus income of US$26 million and a basic loss per unit of US$0.20 from continuing operations. At the same time, the partnership increased funds from operations per unit by about 10% and affirmed a quarterly cash distribution of US$0.4550 per unit, highlighting the contrast between...
NasdaqGM:RYTM
NasdaqGM:RYTMBiotechs

A Look At Rhythm Pharmaceuticals (RYTM) Valuation After IMCIVREE Approvals And Strong First Quarter Results

Rhythm Pharmaceuticals (RYTM) stock has been in focus after a cluster of catalysts, including U.S. and European approvals for IMCIVREE in acquired hypothalamic obesity, as well as first quarter revenue of US$60.11 million alongside a net loss of US$55.64 million. See our latest analysis for Rhythm Pharmaceuticals. The recent approvals and data updates appear to be feeding into Rhythm Pharmaceuticals’ share price performance, with the stock at US$94.17 and a 7 day share price return of 10.04%...
NasdaqCM:CLDX
NasdaqCM:CLDXBiotechs

The Bull Case For Celldex Therapeutics (CLDX) Could Change Following Q1 Loss And Barzolvolimab Milestones

Celldex Therapeutics recently reported first-quarter 2026 results, with revenue falling to US$15,000 from US$695,000 a year earlier and net loss widening to US$78.69 million, while accelerating investment in late-stage development of its lead antibody barzolvolimab. At the same time, Celldex completed Phase 3 enrollment for barzolvolimab in chronic spontaneous urticaria six months ahead of plan and raised about US$345 million in a follow-on offering, extending its funding runway for ongoing...
NasdaqGS:FELE
NasdaqGS:FELEMachinery

A Look At Franklin Electric (FELE) Valuation After Reaffirmed 2026 Earnings And Sales Guidance

Franklin Electric (FELE) is back in focus after reporting first quarter 2026 results and reaffirming its full year net sales guidance, prompting investors to reassess the stock’s risk and income profile. See our latest analysis for Franklin Electric. At a share price of $99.34, Franklin Electric’s short term share price performance has been mixed, with the stock down 8.35% over 90 days but supported by a 1 year total shareholder return of 11.99%, suggesting momentum has cooled after earlier...
NasdaqGM:NBN
NasdaqGM:NBNBanks

A Look At Northeast Bank (NBN) Valuation After Strong Year Over Year Earnings Growth

Key earnings details from Northeast Bank’s latest report Northeast Bank (NBN) posted third quarter results that highlighted year over year changes in profitability, including net interest income of US$63.07 million and net income of US$29.85 million for the period ended March 31, 2026. For the first nine months of the fiscal year, the bank reported net interest income of US$160.07 million and net income of US$73.14 million, giving investors fresh data to assess recent performance and earnings...
NYSE:PCOR
NYSE:PCORSoftware

A Look At Procore Technologies (PCOR) Valuation After Strong Q1 2026 Results And Raised Guidance

Procore Technologies (PCOR) is back in focus after its first quarter 2026 update, which combined higher revenue, a narrower net loss, raised full year guidance, fresh AI moves, and active share repurchases. See our latest analysis for Procore Technologies. Despite the stronger first quarter story and raised 2026 guidance, Procore Technologies' share price return is down 23.9% year to date and total shareholder return is down 26.2% over the past year. The 1 month share price return of 12.9%...
NYSE:BF.B
NYSE:BF.BBeverage

Does Brown-Forman (BF.B)’s Control States Shake-Up Reveal a Deeper Distribution Strategy Shift?

In late April 2026, Brown-Forman Corporation announced it had realigned its U.S. control states distribution network, appointing four key distributors across 11 state-managed spirits markets while retaining existing partners in seven others. This reshaping of distributor relationships, following the end of merger discussions with Pernod Ricard, signals Brown-Forman’s focus on sharpening operational efficiency and market reach. We’ll now examine how this control states distribution overhaul...
NYSE:AGBK
NYSE:AGBKBanks

Is AGI (AGBK) Offering A Rare Opportunity After A 34.8% Year To Date Slide?

Wondering whether AGI at around US$7.01 is a bargain or a value trap? This article walks through the key valuation clues that can help you frame that question. Over the last week the stock gained 2.9%, while over the past month it fell 1.3% and year to date it is down 34.8%. This naturally raises questions about how the market is currently pricing its prospects and risks. Recent coverage has focused on AGI's position in the US banking sector and how its share price has reacted to shifts in...
NasdaqGM:RDNT
NasdaqGM:RDNTHealthcare

RadNet (RDNT) Q1 Loss Widens Again And Tests Bullish AI Margin Narrative

RadNet Q1 2026 earnings: revenue expands while margins stay under pressure RadNet (RDNT) opened 2026 with Q1 revenue of US$575.6 million and a basic EPS loss of US$0.43, as the stock trades around US$58.19. The company has seen revenue move from US$471.4 million in Q1 2025 to US$575.6 million in Q1 2026, while quarterly EPS has shifted from a loss of US$0.51 to a loss of US$0.43 over the same period. This sets up a results season where investors are watching how quickly revenue scale can...
NasdaqGS:STRA
NasdaqGS:STRAConsumer Services

Does AI-Driven Efficiency Amid Softer Enrollment Change The Bull Case For Strategic Education (STRA)?

In its latest quarter, Strategic Education reported mixed results as weaker U.S. enrollment contrasted with improved profitability driven by cost controls and AI-related efficiencies. An interesting takeaway is how AI-enabled operational gains and expense discipline supported earnings even as core enrollment trends showed signs of strain. Next, we'll examine how these AI-driven efficiency gains, alongside softer enrollment, may reshape the existing investment narrative for Strategic...
NYSE:ONON
NYSE:ONONLuxury

Lazard And 2 Stocks That May Be Trading Below Their Estimated Value

Over the last 7 days, the United States market has risen by 2.2%, contributing to a significant 31% increase over the past year, with earnings forecasted to grow by 17% annually. In such a robust environment, identifying stocks that may be trading below their estimated value can offer investors potential opportunities for growth and diversification.
NYSE:RYAN
NYSE:RYANInsurance

Clover Health Investments And 2 Other Insider Picks For Growth

Over the last 7 days, the United States market has risen by 2.2%, contributing to a substantial 31% climb over the past year, with earnings expected to grow by 17% annually. In such an environment, stocks with high insider ownership can be appealing as they often indicate confidence from those closest to the company’s operations and potential for growth, making them noteworthy considerations for investors seeking opportunities in this thriving market.
NasdaqGS:OPK
NasdaqGS:OPKHealthcare

Spotlight On Promising Penny Stocks For May 2026

Over the last 7 days, the United States market has risen by 2.2%, and over the past year, it has increased by 31%, with earnings forecasted to grow annually by 17%. In light of these conditions, investors may find value in smaller or newer companies that offer growth potential at lower price points. Penny stocks, though an outdated term, still represent a viable investment area for those seeking opportunities in companies with strong financial health and long-term potential.